Sodium aurothiomalate

Generic Medicine Info
Indications and Dosage
Progressive juvenile idiopathic arthritis
Child: 1 mg/kg weekly. Max: 50 mg weekly. Calculated initial weekly dose may be preceded by a smaller test dose such as 1/10 or 1/5 of the full dose for 2-3 weeks. Continue weekly doses until signs of remission occur then increase dosage intervals to 2 weeks. With full remission, dosage interval may be increased gradually to 4 weeks. If no improvement after 20 weeks, dose may be raised slightly or another antirheumatic drug may be tried.

Active progressive rheumatoid arthritis
Adult: Initially, 10 mg in the 1st week as test dose, followed by 50 mg weekly until signs of remission occur. Dosage interval is then increased to 2 weeks until full remission, then increased gradually to 4-6 weeks. May continue for up to 5 years after complete remission. Discontinue if no major improvement is seen after a total of 1 g (excluding test dose) has been given, or alternatively, in the absence of toxicity, 100 mg may be given weekly for further 6 weeks. Discontinue if there is no sign of remission.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Exfoliative dermatitis, SLE, necrotising enterocolitis, pulmonary fibrosis. History of haematological disorders, toxicity to heavy metals. Severely debilitated patients. Severe renal or hepatic impairment. Concomitant use w/ antimalarials, immunosuppressive agents, penicillamine or phenylbutazone.
Special Precautions
Patient w/ DM, heart failure, marked HTN, compromised cerebral or CV circulation. History of urticaria, eczema or colitis. Mild to moderate renal or hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Pruritus, stomatitis, erythema multiforme, urticaria, eczema, seborrhoeic dermatitis, lichenoid eruptions, alopecia, exfoliative dermatitis, glossitis, pharyngitis, vaginitis, photosensitivity reactions, chrysiasis, eosinophilia, thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia, proteinuria, haematuria, nephrosis, pulmonary fibrosis, dyspnoea, toxic hepatitis, cholestatic jaundice, peripheral neuritis, encephalitis, psychoses, fever, weakness, flushing, palpitations, syncope. Rarely, iritis, corneal ulcers, golds deposit in the eye.
Potentially Fatal: Rarely, ulcerative colitis.
Monitoring Parameters
Perform CBC w/ differential, platelet count, urinalysis for protein and LFT prior to initiation of therapy. Skin and oral mucosa inspection.
Drug Interactions
Drug Interaction: May increase risk of aspirin-induced liver damage. Increased risk of severe anaphylactoid reaction when used w/ ACE inhibitors.
Potentially Fatal: Increased risk of blood dyscrasias and other severe adverse effects (e.g. proteinuria) when used concomitantly w/ myelossupressive agents, phenylbutazone, penicillamine and antimalarials.
Lab Interference
May interfere w/ serum protein-bound iodine measurement by chloric acid digestion method.
Mechanism of Action: Sodium aurothiomalate is a disease-modifying antirheumatic drug, used in patients whose symptoms are unresponsive to or inadequately controlled by NSAID alone. The exact mechanism of action has not been established, but its predominant action appears to be a suppressive effect on the synovitis of active rheumatoid disease. It may act by altering function of other enzymes by inhibiting lysosomal enzymes, by suppressing phagocytic activity of macrophages and polymorphonuclear leukocytes, or by altering immune response.
Onset: Delayed; may require up to 3 mth.
Absorption: Readily absorbed after IM inj. Time to peak serum concentration: 4-6 hr.
Distribution: Widely distributed in body tissues and fluids. Crosses placenta and enters breast milk. Plasma protein binding: 85-95%.
Excretion: Via urine (60%-90%) and faeces (10%-40%). Elimination half-life: Approx 5-6 days.
Chemical Structure

Chemical Structure Image
Sodium aurothiomalate

Source: National Center for Biotechnology Information. PubChem Database. Sodium aurothiomalate, CID=22318, (accessed on Jan. 23, 2020)

Store between 15-30°C. Protect from light.
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
ATC Classification
M01CB01 - sodium aurothiomalate ; Belongs to the class of gold preparations of antirheumatic agents.
Anon. Gold Sodium Thiomalate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 12/07/2016.

Buckingham R (ed). Sodium aurothiomalate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 12/07/2016.

Joint Formulary Committee. Sodium aurothiomalate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 12/07/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Aurothioglucose, Gold Sodium Thiomalate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 12/07/2016.

Myochrysine Injection (Akorn, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 12/07/2016.

Disclaimer: This information is independently developed by MIMS based on Sodium aurothiomalate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in